Patents by Inventor A-Rum Yoon

A-Rum Yoon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Complex of adenovirus and PAMAM-PEG-Erbitux, and use thereof
    Patent number: 10849987
    Abstract: The present invention relates to a complex of an antitumor adenovirus coated with ErbB-PEG-PAMAM and the use thereof. When using the complex of the present invention, a tumor cell-specific gene transfer effect by an excellent tumor cell infiltration ability is excellent, hepatotoxicity is low, a blood flow retention time is prolonged. Thus, the complex of the present invention can be used as a pharmaceutical composition for the treatment of a tumor and a gene therapy agent which can be administered systemically.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: December 1, 2020
    Inventors: Chae Ok Yun, A-Rum Yoon
  • COMPLEX OF ADENOVIRUS AND PAMAM-PEG-ERBITUX, AND USE THEREOF
    Publication number: 20190134218
    Abstract: The present invention relates to a complex of an antitumor adenovirus coated with ErbB-PEG-PAMAM and the use thereof. When using the complex of the present invention, a tumor cell-specific gene transfer effect by an excellent tumor cell infiltration ability is excellent, hepatotoxicity is low, a blood flow retention time is prolonged. Thus, the complex of the present invention can be used as a pharmaceutical composition for the treatment of a tumor and a gene therapy agent which can be administered systemically.
    Type: Application
    Filed: September 7, 2018
    Publication date: May 9, 2019
    Inventors: Chae Ok YUN, A-Rum YOON
  • Gene delivery system having enhanced tumor-specific expression, and recombinant gene expression regulating sequence
    Patent number: 9689000
    Abstract: The present invention relates to a gene expression regulating sequence consisting of a combination of HRE, E2F and TERT, and to a gene delivery system having significantly improved selective tumor cell cytotoxicity using same, and more particularly, to a recombinant adenovirus. In addition, the present invention relates to a pharmaceutical antitumor composition comprising the recombinant adenovirus. The replication of the recombinant adenovirus of the present invention is tumor-specifically regulated by the novel gene expression regulating sequence of the present invention, thus enabling the recombinant adenovirus of the present invention to exhibit improved selective tumor cell cytotoxicity or apoptotic potential, and exhibit remarkably improved antitumor effects particularly in hypoxic conditions. In addition, the specific expression of the recombinant adenovirus in tumor cells may increase in vivo stability, and thus may induce greatly improved antitumor effects.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: June 27, 2017
    Assignee: GENEMEDICINE CO., LTD.
    Inventors: Chae Ok Yun, A-Rum Yoon
  • GENE DELIVERY SYSTEM HAVING ENHANCED TUMOR-SPECIFIC EXPRESSION, AND RECOMBINANT GENE EXPRESSION REGULATING SEQUENCE
    Publication number: 20130323206
    Abstract: The present invention relates to a gene expression regulating sequence consisting of a combination of HRE, E2F and TERT, and to a gene delivery system having significantly improved selective tumor cell cytotoxicity using same, and more particularly, to a recombinant adenovirus. In addition, the present invention relates to a pharmaceutical antitumor composition comprising the recombinant adenovirus. The replication of the recombinant adenovirus of the present invention is tumor-specifically regulated by the novel gene expression regulating sequence of the present invention, thus enabling the recombinant adenovirus of the present invention to exhibit improved selective tumor cell cytotoxicity or apoptotic potential, and exhibit remarkably improved antitumor effects particularly in hypoxic conditions. In addition, the specific expression of the recombinant adenovirus in tumor cells may increase in vivo stability, and thus may induce greatly improved antitumor effects.
    Type: Application
    Filed: June 28, 2011
    Publication date: December 5, 2013
    Applicant: Industry-University Cooperation Foundation Hanyang University
    Inventors: Chae Ok Yun, A-Rum Yoon